Up to now, 31 clinical trials are registered with 11 different CAR targets (CD19, CD20, CD22, NKG2D-L, CD33, and BCMA on the top) to address the clinical efficacy of CAR-NK cells in hematologic tumors (Table 1) (22, 34). Here, CD19 is linked to hematopoietic and lymphoid cell neoplasm.